[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601974":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":62,"overallOfficials":11,"centralContacts":68,"locations":74,"responsibleParty":95,"collaborators":11,"id":97,"slug":11,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":11,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":11,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":11,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of any adverse events",null,"Evaluation was performed up to Day169",[14,17,19,21,23,25,27,29,31],{"measure":15,"description":11,"timeFrame":16},"Maximum observed plasma concentration of HRS-9563 (Cmax)","Evaluation was performed up to Day3",{"measure":18,"description":11,"timeFrame":16},"Time to Cmax (Tmax)",{"measure":20,"description":11,"timeFrame":16},"Area under the concentration-time curve from 0 to the last measurable time point after HRS-9563 administration (AUC0-t)",{"measure":22,"description":11,"timeFrame":16},"Area under the concentration-time curve from time 0 to infinity after HRS-9563 administration (AUC0-inf)",{"measure":24,"description":11,"timeFrame":16},"Terminal elimination half-life of HRS-9563 (t1\u002F2",{"measure":26,"description":11,"timeFrame":16},"Apparent clearance of HRS-9563 (CL\u002FF)",{"measure":28,"description":11,"timeFrame":16},"Apparent volume of distribution during terminal elimination phase of HRS-9563 (Vz\u002FF)",{"measure":30,"description":11,"timeFrame":16},"Cumulative amount of drug excreted in urine (Ae,urine)",{"measure":32,"description":11,"timeFrame":16},"Cumulative percentage of dose recovered in urine (Fe,urine)",{"allocation":34,"interventionModel":35,"interventionModelDescription":11,"primaryPurpose":36,"observationalModel":11,"timePerspective":11,"maskingInfo":37},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":38,"maskingDescription":11,"whoMasked":39},"QUADRUPLE",[40,41,42,43],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[45,50,53,56,59],{"label":46,"type":47,"description":11,"interventionNames":48},"Treatment group 1: Injection of HRS-9563 or placebo","EXPERIMENTAL",[49],"Drug: HRS-9563, placebo",{"label":51,"type":47,"description":11,"interventionNames":52},"Treatment group 2: Injection of HRS-9563 or placebo",[49],{"label":54,"type":47,"description":11,"interventionNames":55},"Treatment group 3: Injection of HRS-9563 or placebo",[49],{"label":57,"type":47,"description":11,"interventionNames":58},"Treatment group 4: Injection of HRS-9563 or placebo",[49],{"label":60,"type":47,"description":11,"interventionNames":61},"Treatment group 5: Injection of HRS-9563 or placebo",[49],[63],{"type":64,"name":65,"description":66,"armGroupLabels":67,"otherNames":11},"DRUG","HRS-9563, placebo","A single subcutaneous injection of HRS-9563 injection or placebo was administered",[46,51,54,57,60],[69],{"name":70,"role":71,"phone":72,"phoneExt":11,"email":73},"Yuhan Guo","CONTACT","+0518-81220121","yuhan.guo.yg21@hengrui.com",[75],{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Zhejiang Provincial People's Hospital","RECRUITING","Hangzhou","Zhejiang","314408","China","CN",{"type":84,"coordinates":85},"Point",[86,87],120.16142,30.29365,{"lat":87,"lon":86},[90,93],{"name":91,"role":92,"phone":11,"phoneExt":11,"email":11},"Yiwen Zhang","PRINCIPAL_INVESTIGATOR",{"name":94,"role":92,"phone":11,"phoneExt":11,"email":11},"Ping Huang",{"type":96,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601974",false,"NCT07117474","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.","Inclusion Criteria:\n\n1. Males or infertile women aged 18-65 years (inclusive);\n2. Body mass index in the range of 19-28 kg\u002Fm2 (inclusive);\n3. Mild primary hypertension, without antihypertensive treatment, with a mean sitting systolic blood pressure ≥ 130 mmHg and ≤ 159 mmHg during screening and baseline, and a mean 24-hour ambulatory systolic blood pressure ≥ 130 mmHg during screening.\n\nExclusion Criteria:\n\n1. Abnormal daily life rhythm;\n2. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;\n3. Secondary hypertension;\n4. Mean sitting diastolic blood pressure ≥ 100 mmHg;\n5. Orthostatic hypotension;\n6. History of type 2 diabetes mellitus or poorly controlled blood glucose;\n7. Recently received any antihypertensive medications or medications that affect blood pressure.",true,"ALL","18 Years","65 Years",{"count":107,"type":108},60,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects",[114],"Subjects With Mild Hypertension","2025-08-04",{"date":117,"type":118},"2025-08-12","ACTUAL",{"date":120,"type":118},"2024-12-24",{"date":122,"type":108},"2025-12",{"name":5,"class":6},1]